Therefore, the pronounced improvement of sorafenib efficacy in GHA mice, as well as marked suppression of HCC allografts even in untreated GHA mice can be reasonably hypothesized to be a cumulative effect of GHR inhibition and lower IGF1 levels. This evidence concerns the gene IGF1 and hepatocellular carcinoma.